Atezolizumab for Lynch Syndrome
Study Summary
This trial is testing a combination of chemotherapy drugs with atezolizumab to see if it is more effective than chemotherapy alone in treating patients with stage III colon cancer. Atezolizumab is an immunotherapy drug that may help the body's immune system attack the cancer.
- Lynch Syndrome
- Malignant Neoplasms
- Adenocarcinoma
- DNA Repair Disorder
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: From the time from randomization to death, from any cause, assessed up to 5 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
2 Treatment Groups
Arm II (combination chemotherapy)
1 of 2
Arm I (combination chemotherapy, atezolizumab)
1 of 2
Active Control
Experimental Treatment
700 Total Participants · 2 Treatment Groups
Primary Treatment: Atezolizumab · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 8th, 2021
Last Reviewed: November 29th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| Alabama | 100.0% |
How old are they?
| 65+ | 100.0% |
What site did they apply to?
| Cookeville Regional Medical Center | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |